Targeting of nuclear factor-κB and proteasome by dithiocarbamate complexes with metals

Current Pharmaceutical Design

Volumn 13, Issue 30, 2007, Pages 3155-3167

  Cvek, B ^a,b   Dvorak, Z ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

^b NONE   (Czech Republic)

Author keywords

Diethyldithiocarbamate (DDTC); Disulfiram; JAMM; Metal dithiocarbamates; NF B; Proteasome; Pyrrolidinedithiocarbamate (PDTC)

Indexed keywords

ALDEHYDE DERIVATIVE; ANTIDOTE; ANTINEOPLASTIC AGENT; BETA LACTONE DERIVATIVE; BORONIC ACID DERIVATIVE; BORTEZOMIB; DIETHYLDITHIOCARBAMIC ACID; DISULFIRAM; DITHIOCARBAMIC ACID; DITHIOCARBAMIC ACID DERIVATIVE; EPOXYKETONE DERIVATIVE; ETHYLDITHIOCARBAMIC ACID; ETHYLMETHYLDITHIOCARBAMIC ACID; GLUCONATE ZINC; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PESTICIDE; PROTEASOME; PROTEASOME INHIBITOR; PYRROLIDINEDITHIOCARBAMIC ACID; TRANSITION ELEMENT; UNCLASSIFIED DRUG; VINYL SULFONE DERIVATIVE; ZINC; ZINC DIBENZYLDITHIOCARBAMIC ACID;

ALCOHOLISM; APOPTOSIS; CANCER THERAPY; CYTOTOXICITY; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOXICITY; DRUG WITHDRAWAL; ENZYME INHIBITION; EYE CANCER; HUMAN; IMMUNE SYSTEM; INTOXICATION; LIVER INJURY; LIVER TOXICITY; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; DITIOCARB; HUMANS; METALS; NF-KAPPA B; PROTEASOME ENDOPEPTIDASE COMPLEX; SIGNAL TRANSDUCTION; THIOCARBAMATES;

EID: 36349012493     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207782110390     Document Type: Review

References (344)

1. Thorn GD, Ludwig RA. The dithiocarbamates and related compounds, Amsterdam, Elsevier Publishing Co. 1962.
2. Bond AM, Martin RL. Electrochemistry and redox behavior of transition-metal dithiocarbamates. Coord Chem Rev 1984; 54: 23-98.
3. Fay RC. Stereochemistry and molecular rearrangements of some six-, seven- mid eight-coordinate chelates of early transition metals. Coord Chem Rev 1996; 154: 99-124.
4. Plyusnin VF, Grivin VP, Larionov SV. Photochemistry of Fe(III), Fe(IV), Ru(III), Mo(VI), and Ni(IV) dithiocarbamate complexes. Coord Chem Rev 1997; 159: 121-33.
5. Laguna A, Laguna M. Coordination chemistry of gold(II) complexes. Coord Chem Rev 1999; 193-5: 837-56.
6. Victoriano LI. The reactivity of metal species towards thiuram sulfides: an alternative route to the syntheses of metal dithiocarbamates. Coord Chem Rev 2000; 196: 383-98.
7. 2 complexes with dimethyl acetylenedicarboxylate and phenylacetylene. Organometallics 2000; 19: 5643-53.
8. Garje SS, Jain VK. Chemistry of arsenic, antimony and bismuth compounds derived from xanthate, dithiocarbamate and phosphoras based ligands. Coord Chem Rev 2003; 236: 35-56.
9. van Koningsbruggen PJ, Maeda Y, OEM H. Iron(III) spin cross-over compounds. Top Curr Chem 2004; 233: 259-324.
10. 13C CP/MAS NMR of dialkyldithiocarbamate compounds with Ni(II) and Zn(II). Top Curr Chem 2005; 246: 271-337.
11. Nieuwenhuizen PJ, Reedijk J, van Duin M, McGill WJ. Thiuramand dithiocarbamate-accelerated sulfur vulcanization from the chemist's perspective. Methods, materials and mechanisms reviewed. Rubber Chem Technol 1997; 70: 368-429.
12. Kurian JK, Peethambaran NR, Mary KC, Kuriakose B. Effect of vulcanization systems and antioxidants on discoloration and degradation of natural rubber latex thread under UV radiation. J Appl Polym Sci 2000; 78: 304-10.
13. Bond AM, Wallace GG. Determination of copper as a dithiocarbamate complex by reversed-phase liquid-chromatography with electrochemical detection. Anal Chem 1981; 53: 1209-13.
14. Lo JM, Yu JC, Hutchison FI, Wal CM. Solvent-extraction of dithiocarbamate complexes and back-extraction with mercury(II) for determination of trace-metals in sea-water by atomic-absorption spectrometry. Anal Chem 1982; 54: 2536-9.
15. Zhang TH, Shan XQ, Liu RX, Tang HX, Zhang SZ. Preconcentration of rare earth elements in seawater with poly(acrylaminophosphonicdithiocarbamate) chelating fiber prior to determination by inductively coupled plasma mass spectrometry. Anal Chem 1998; 70: 3964-8.
16. Environmental Health Criteria, World Health Organization, Vammal, 1988.
17. Vettorazzi G, Almeida WF, Burin GJ, Jaeger RB, Puga FR, Rahde AF, et al. International safety assessment of pesticides: Dithiocarbamate pesticides, ETU, and PTU - A review and update. Yeratog Carcinog Mutagen 1995; 15: 313-37.
18. Vaccari A, Saba P, Mocci I, Ruiu S. Dithiocarbamate pesticides affect glutamate transport in brain synaptic vesicles. J Pharmacol Exp Ther 1999; 288: 1-5.
19. Soloneski S, Gonzalez M, Piaggio E, Apezteguia M, Reigosa MA, Larramendy ML. Effect of the dithiocarbamate pesticide zineb and its commercial formulation, azzurro. I. Genotoxic evaluation on cultured human lymphocytes exposed in vitro. Mutagenesis 2001; 16: 487-93.
20. Soloneski S, Reigosa MA, Larramendy ML. Effect of the dithiocarbamate pesticide zineb and its commercial formulation, azzurro. II. Micronucleus induction in immunophenotyped human lymphocytes. Environ Mol Mutagen 2002; 40: 57-62.
21. Soloneski S, Gonzalez M, Piaggio E, Reigosa MA, Larramendy ML. Effect of the dithiocarbamate pesticide zineb and its commercial formulation, azzurro. III. Genotoxic evaluation on Chinese hamster ovary (CHO) cells. Mutat Res 2002; 514: 201-12.
22. Gonzalez M, Soloneski S, Reigosa MA, Larramendy ML. Effect of the dithiocarbamate pesticide zineb and its commercial formulation, azzurro. IV. DNA damage and repair kinetics assessed by single cell gel electrophoresis (SCGE) assay on Chinese hamster ovary (CHO) cells. Murat Res 2003; 534: 145-54.
23. Soloneski S, Reigosa MA, Larramendy ML. Effect of the dithiocarbamate pesticide zineb and its commercial formulation, azzurro. V. Abnormalities induced in the spindle apparatus of transformed and non-transformed mammalian cell lines. Mutat Res 2003; 536: 121-9.
24. Stoker TE, Jeffay SC, Zucker RM, Cooper RL, Perreault SD. Abnormal fertilization is responsible for reduced fecundity following thiram-induced ovulatory delay in the rat. Biol Reprod 2003; 68: 2142-9.
25. Calviello G, Piccioni E, Boninsegna A, Tedesco B, Maggiano N, Serini S, et al. DNA damage and apoptosis induction by the pesticide mancozeb in rat cells: Involvement of the oxidative mechanism. Toxicol Appl Pharmacol 2006; 211: 87-96.
26. Fitsanakis VA, Amamath V, Moore JT, Montine KS, Zhang J, Montine TJ. Catalysis of catechol oxidation by metal-dithiocarbamate complexes in pesticides. Free Radic Biol Med 2002; 33: 1714-23.
27. Zhang J, Fitsanakis VA, Gu GY, Jing DQ, Ao MF, Amarnath V, et al. Manganese ethylene-bis-dithiocarbamate and selective dopaminergic neurodegeneration in rat: A link through mitochondrial dysfunction. J Neurochem 2003; 84: 336-46.
28. Barlow BK, Thiruchelvam MJ, Bennice L, Cory-Slechta DA, Ballatori N, Richfield EK. Increased synaptosomal dopamine content and brain concentration of paraquat produced by selective. dithiocarbamates. J Neurochem 2003; 85: 1075-86.
29. Uversky VN. Neurotoxicant-induced animal models of Parkinson's disease: understanding the role of rotenone, maneb and paraquat in neurodegeneration. Cell Tissue Res 2004; 318: 225-41.
30. Li AA, Mink PJ, McIntosh LJ, Teta MJ, Finley B. Evaluation of epidemiologic and animal data associating pesticides with Parkinson's disease. J Occup Environ Med 2005; 47: 1059-87.
31. Thiruchelvam M, Prokopenko O, Cory-Slechta DA, Richfield EK, Buckley A. Mirochnitchenko O. Overexpression of superoxide dismutase or glutathione peroxidase protects against the paraquat + maneb-induced Parkinson disease phenotype. J Biol Chem 2005; 280: 22530-9.
32. Brown TP, Rumsby PC, Capleton AC, Rushton L, Levy LS. Pesticides and Parkinson's disease - is there a link? Environ Health Perspect 2006;. 114: 156-64.
33. Sunderman FW. Efficacy of sodium diethyldithiocabamate (dithiocarb) in acute nickel carbonyl poisoning. Ann Clin Lab Sci 1979; 9: 1-10.
34. Jone SG, Jones MM. Structure-activity-relationships among dithiocarbamate antidotes for acute cadmium chloride intoxication. Environ Health Perspect 1984; 54: 285-90.
35. Macias B. Criado JJ, Vaquero MV, Villa MV, Castillo M. Dithlocarbamate derivatives from α-amino acids as chelating agents for toxic metal ions. J Inorg Biochem 1991;,42: 17-24.
36. Tandon SK, Kachru DN. Chelation in metal intoxication. 36. Effect of substituted piperazine dithiocarbamates in lead exposed rats. Acta Pharmacol Sin 1991; 12: 391-4.
37. Blanusa M, Varnai VM, Piasek M, Kostial K. Chelators as antidotes of metal toxicity: Therapeutic and experimental aspects. Curr Med Chem 2005; 12: 2771-94.
38. Bodenner DL, Dedon PC, Keng PC, Borch RF. Effect of diethyldithiocarbamate on cis-diamminedicholoroplatinum(II)-induced cytotoxicity, DNA cross-linking, and gamma-glutamyltransferase transpeptidase inhibition. Cancer Res 1986; 46: 2745-
39. Bothenberg ML, Ostchega Y, Steinberg SM, Young RC, Hummel S, Ozols RF. High-dose carboplatin with diethyldithiocarbamate chemoprotection in treatment of women with relapsed ovarian cancer. J Natl Cancer Inst 1988; 80: 1488-92.
40. Berry JM, Jacobs C, Sikic B, Halsey J, Borch RF. Modification of cisplatin toxicity with diethyldithiocarbamate. J Clin Oncol 1990; 8: 1585-90.
41. Bouvet D, Michalowicz A, Crauste-Manciet S, Brossard D, Provost K. EXAFS and IR structural study of platinum-based anticancer drugs' degradation by diethyl dithiocarbamate. Inorg Chem 2006; 45: 3393-8.
42. Lai CS, Komarov AM. Spin trapping of nitric oxide produced in vivo in septic shock mice. FEBS Lett 1994; 345: 120-4.
43. Zweier JL, Wang PH, Kuppusamy P. Direct measurement of nitric oxide generation in the ischemic heart using electron paramagnetic resonance spectroscopy. J Biol Chem 1995; 270: 304-7.
44. Xia Y, Zweier JL. Direct measurement of nitric oxide generation from nitric oxide synthese. Proc Natl Acad Sci USA 1997; 94: 12705-10.
45. Fujii H, Berliner LJ. Ex vivo EPR detection of nitric oxide in brain tissue. Magn Reson Med 1999; 42: 599-602.
46. Tsuchiya K, Yoshizumi M, Houchi H, Mason RP. Nitric oxide forming reaction between the iron-N-methyl-D-glucamine dithiocarbamate complex and nitrite. J Biol Chem 2000; 275: 1551-6.
47. Fujii S, Yoshimura T. A new trend in iron-dithiocarbamate complexes: As an endogenous NO trapping agent. Coord Chem Rev 2000; 198: 89-99.
48. Xia Y, Cardounel AJ, Vanin AF, Zweier JL. Electron paramagnetic resonance spectroscopy with N-methyl-D-glucamine dithiocarbamate iron complexes distinguishes nitric oxide and nitroxyl anion in a redox-dependent manner: Applications in identifying nitrogen monoxide products from nitric oxide synthese. Free Radic Biol Med 2000; 29: 793-7.
49. Venkataraman S, Martin SM, Buettner GR. Electron paramagnetic resonance for quantitation of nitric oxide in aqueous solutions. Methods Enzymol 2002; 359: 3-18.
50. Weaver J, Porasuphatana S, Tsai P, Budzichowski T, Rosen GM. Spin trapping nitric oxide from neuronal nitric oxide synthase: A look at several iron-dithiocarbamate complexes. Free Radic Res 2005; 39: 1027-33.
51. Vanin AF, Poltorakov AP, Mikoyan VD, Kubrina LN, van Faassen E. Why iron-dithiocarbamates ensure detection of nitric oxide in cells and tissues. Nitric Oxide 2006; 15: 295-311.
52. Vanin AF, Bevers LM, Mikoyan VD, Poltorakov AP, Kubrina LN, van Faassen E. Reduction enhances yields of nitric oxide trapping by iron-diethyldithiocarbamate complex in biological systems. Nitric Oxide 2007; 16: 71-81.
53. Wheeler HL, Merriam HF. On the action of alkyl thiocyanates and alkyl isothiocyanates with thiol acids. J Am Chem Soc 1901; 23: 283-99.
54. Delepine M. Metallic salts of dithiocarbamic acids; preparation of isothiocyanates in aliphatic series. Compt Rend 1907; 144: 1125-7.
55. Bedford CW, Scott W. Reactions of accelerators during vulcanization. Ind Eng Chem 1920; 12: 31-3.
56. Chatt J, Duncanson LA, Venanzi LM. Electronic structures of dithiocarbamates and xanthates. Nature 1956; 177: 1042-3.
57. Vanngard T, Akerstrom S. Electron spin resonance and divalency of some dithiocarbamates of the coinage metals (Cu, Ag, Au). Nature 1959; 184: 183-4.
58. Halls DJ. The properties of dithiocarbamates - a review. Mikrochim Acta 1969; 62-77.
59. Steggerda JJ, Cras JA, Willemse J. Reactions of complexes of dithiocarbamate and related ligands. Recl Trav Chim Pays Bas 1981; 100: 41-8.
60. Topping RJ, Jones MM. Optimal dithiocarbamate structure for immunomodulator action. Med Hypotheses 1988; 27: 55-7.
61. Eneanya DI, Bianchine JR, Duran DO, Andresen BD. The actions and metabolic fate of disulfiram. Annu Rev Pharmacol Toxicol 1981; 21: 575-96.
62. Hald J, Jacobsen E. A drug sensitizing the organism to ethyl alcohol. Lancet 1948; 252: 1001-4.
63. Hughes JC, Cook CCH. The efficacy of disulfiram: A review of outcome studies. Addiction 1997; 92: 381-95.
64. Singh AN, Srivastava S, Jainar AK. Pharmacotherapy of chronic-alcoholism: A review. Drugs Today (Barc) 1999; 35: 27-33.
65. Garbutt JC, West SL, Carey TS, Lohr KN, Crews FT. Pharmacological treatment of alcohol dependence - a review of the evidence. JAMA 1999; 281: 1318-25.
66. Mann K. Pharmacotherapy of alcohol dependence - a review of the clinical data. CNS Drugs 2004; 18: 485-504.
67. Kenna GA, McGeary JE, Swift RM. Pharmacotherapy, pharmacogenomics, and the future of alcohol dependence treatment, part 1. Am J Health Syst Pharm 2004; 61: 2272-9.
68. Kenna GA, McGeary JE, Swift RM. Pharmacotherapy, pharmacogenomics, and the future of alcohol dependence treatment, part 2. Am J Health Syst Pharm 2004; 61: 2380-8.
69. Soyka M, Roesner S. New pharmacological approaches for the treatment of alcoholism. Expert Opin Pharmacother 2006; 7: 2341-53.
70. Gorelick DA, Gardner EL, Xi ZX. Agents in development for the management of cocaine abuse. Drugs 2004; 64: 1547-73.
71. Sofuoglu M, Kosten TR. Novel approaches to the treatment of cocaine addiction. CNS Drugs 2005; 19: 13-25.
72. Suh JJ, Pettinati HM, Kampman KM, O'Brien CP. The status of disulfiram: a half of a century later. J Clin Psychofarmacol 2006; 26: 290-302.
73. Wiesbeck G, Duersteler-MacFarland K. New developments in the pharmacotherapy of cocaine dependence. Nervenarzt 2006; 77: 1064-70
74. Vallari, RC, Pietruszko R. Human aldehyde dehydrogenase: Mechanism of inhibition by disulfiram. Science 1982; 216: 637-9.
75. Kitson TM. Mechanism of inactivation of sheep liver cytoplasmic aldehyde dehydrogenase by disulfiram. Biochem J 1983; 213: 551-4.
76. Sanny CG, Weiner H. Inactivation of horse liver mitochondrial aldehyde dehydrogenase by disulfiram. Biochem J 1987; 242: 499-503.
77. Shen ML, Lipsky JJ, Naylor S. Role of disulfiram in the in vitro inhibition of rat liver mitochondrial aldehyde dehydrogenase. Biochem Pharmacol 2000; 60: 947-53.
78. Johansson B, Petersen EN, Arnold E. Diethylthiocarbamic acid methyl ester: A potent inhibitor of aldehyde dehydrogenase found in rats treated with disulfiram or diethyldithiocarbamic acid methyl ester. Biochem Pharmacol 1989; 38: 1053-9.
79. Helander A, Johansson B. Inhibition of human erythrocyte and leukocyte aldehyde dehydrogenase activities by diethylthiocarbamic acid methyl ester - an in vivo metabolite of disulfiram. Biochem Pharmacol 1989; 38: 2195-8.
80. Johansson B, Stankiewicz Z. Inhibition of erythrocyte aldehyde dehydrogenase activity and elimination kinetics of diethyldithiocarbamic acid methyl ester and its monothio analog after administration of single and repeated doses of disulfiram to man. Eur J Clin Pharmacol 1989; 37: 133-8.
81. m aldehyde dehydrogenase. Biochem Pharmacol 1991; 42: 1361-6.
82. Johansson B. A review of the pharmacokinetics and pharmacodynamics of disulfiram and its metabolites. Acta Psychiatr Scand 1992; 86: 15-26.
83. Jin LX, Davis MR, Hu P, Baillie TA. Identification of novel glutathione conjugates of disulfiram and diethyldithiocarbamate in rat bile by liquid chromatography tandem mass spectrometry - evidence for metabolic activation of disulfiram in vivo. Chem Res Toxicol 1994; 7: 526-33.
84. Veverka KA, Johnson KL, Mays DC, Lipsky JJ, Naylor S. Inhibition of aldehyde dehydrogenase by disulfiram and its metabolite methyl diethylthiocarbamoylsulfoxide. Biochem Pharmacol 1997; 53: 511-8.
85. Hart BW, Faiman MD. Bioactivation of S-methyl-N,N-diethylthiolcarbamate to S-methyl-N,N-diethylthiolcarbamate sulfoxide - implications for the role of cytochrome P450. Biochem Pharmacol 1993; 46: 2285-90.
86. Madan A, Parkinson A, Faiman MD. Role of flavin-dependent monooxygenases and cytochrome P450 enzymes in the sulfoxidation of S-methyl-N,N-diethylthiolcarbamate. Biochem Pharmacol 1993; 46: 2291-7.
87. Shen ML, Johnson KL, Mays DC, Lipsky JJ, Naylor S. Determination of in vivo adducts of disulfiram with mitochondrial aldehyde dehydrogenase. Biochem Pharmacol 2001; 61: 537-45.
88. Lipsky JL, Shen ML, Naylor S. Overview - in vitro inhibition of aldehyde dehydrogenase by disulfiram and metabolites. Chem Biol Interact 2001; 130: 81-91.
89. Martens T, Langevin-Bermond D, Fleury MB. Ditiocarb: Decomposition in aqueous solution and effect of the volatile products on its pharmacological use. J Pharm Sci 1993; 82: 379-83.
90. Valentine WM, Amarnath V, Amarnath K, Rimmele F, Graham DG. Carbon disulfide mediated protein cross-linking by N,N-dimethyldithiocarbamate. Chem Res Toxicol 1995; 8: 96-102.
91. Neims AH, Coffey DS, Hellerma L. Interaction between tetraethylthiuram disulflde and sulfhydryl groups of D-aminoacid oxidase and of hemoglobin. J Biol Chem 1966; 241: 5941-8.
92. Kumar KS, Sancho AM, Weiss JF. A novel interaction of diethyldithiocarbamate with glutathione glutathione-peroxidase system. Int J Radiat Oncol Biol Phys 1986; 12: 1463-7.
93. Hosni M, Meskini N, Prigent AF, Anker G, Joulain C, Elhabib R, et al. Diethyldithiocarbamate (ditiocarb sodium) effect on arachidonic acid metabolism in human mononuclear cells - glutathione-peroxidase-like activity. Biochem Pharmacol 1992; 43: 1319-29.
94. Zemaitis MA, Greene FE. In vivo and in vitro effects of thiuram disulfides and dithiocarbamates on hepatic microsomal drug metabolism in the rat. Toxicol Appl Pharmacol 1979; 48: 343-50.
95. Dierickx PJ. In vitro interaction of dithiocarb with rat liver glutathione S-transferases. Pharmacol Res Commun 1984; 16: 135-43.
96. Kelner MJ, Alexander NM. Inhibition of erythrocyte superoxide dismutase by diethyldithiocarbamate also results in oxyhemoglobin-catalyzed glutathione depletion and methemoglobin production. J Biol Chem 1986; 261: 1636-41.
97. Kelner MJ, Bagnell R, Hale B, Alexander NM. Inactivation of intracellular copper-zinc superoxide dismutase by copper chelating agents without glutathione depletion and methemoglobin formation. Free Radic Biol Med 1989; 6: 355-60.
98. Pompidou A, Renoux M, Guillaumin JM, Mace B, Michel P, Coutance F, et al. Kinetics of the histological changes in lymphoid organs and of the T-cell inducing capacity of serum in mice treated with imuthiol (sodium diethyldithiocarbamate). Int Arch Allergy Appl Immunol 1984; 74: 172-7.
99. Pompidou A, Duchet N, Cooper MD, Mace B, Telvi L, Coutance F, et al. The generation and regulation of human lymphocytes T by imuthiol - evidence from an in vitro differentiation induction system. Int J Immunopharmacol 1985; 7: 561-6.
100. Pompidou A, Delsaux MC, Telvi L, Mace B, Coutance F, Falkenrodt A, et al. Isoprinosine and imuthiol, two potentially active compounds in patients with AIDS-related complex symptoms. Cancer Res 1985; 45: 4671-3.
101. Lemarie E, Musset M, Charbonnier C, Renoux M, Renoux G. Clinical characterization of imuthiol. Methods Find Exp Clin Pharmacol 1986; 8: 51-4.
102. Lang JM, Trepo C, Kirstetter M, Herviou L, Retornaz G, Renoux G, et al. Randomized, double blind, placebo controlled trial of ditiocarb sodium (imuthiol) in human immunodeficiciency virus infection. Lancet 1988; 2: 702-6.
103. Abrams DI. Alternative therapies in HIV infection. AIDS 1990; 4: 1179-87.
104. Sunderman FW. Therapeutic properties of sodium diethyldithiocarbamate - its role as an inhibitor in the progression of AIDS. Ann Clin Lab Sci 1991; 21: 70-81.
105. Hersh EM, Brewton G, Abrams D, Bartlett J, Galpin J, Gill P, et al. Ditiocarb sodium (diethyldithiocarbamate) therapy in patients with symptomatic HIV infection and AIDS. A randomized, double-blind, placebo controlled, multicenter study. JAMA 1991; 265: 1538-44.
106. Picolet H, Lang JM, Touraine JL, Livrozet JM, Saintmarc T, Kirstetter M, et al. Multicenter, randomized, placebo-controlled study of ditiocarb (imuthiol) in human immunodeficiency virus-infected asymptomatic and minimally symptomatic patients. AIDS Res Hum Retroviruses 1993; 9: 83-9.
107. Benson EM. Immune modulation in HIV infection: Fact or fantasy? J Acquir Immune Defic Syndr Hum Retrovirol 1993; 6: S61-7.
108. Misra HP. Reaction of copper-zinc superoxide dismutase with diethylithiocarbamate. J Biol Chem 1979; 254: 11623-8.
109. Cocco D, Calabrese L, Rigo A, Argese E, Rotilio G. Reexamination of the reaction of diethyldithiocarbamate with the copper of superoxide dismutase. J Biol Chem 1981; 256: 8983-6.
110. Bonamico M, Dessy G, Mugnoli A, Vaciago X, Zambonelli L. Structural studies of metal dithiocarbamates. II. The crystal and molecular structure of copper diethyldithiocarbamate. Acta Crystallogr 1965; 19: 886-97.
111. Cocco D, Calabrese L, Rigo A, Marmocchi F, Rotilio G. Preparation of selectively metal free and metal substituted derivatives by reaction of Cu-Zn superoxide dismutase with diethyldithiocarbamate. Biochem J 1981; 199: 675-80.
112. Heikkila RE, Cabbat FS, Cohen G. In vivo inhibition of superoxide dismutase in mice by diethyldithiocarbamate. J Biol Chem 1976; 251: 2182-5.
113. Kim SM, Kang JH. Peroxidative activity of human Cu,Zn-superoxide dismutase. Mol Cells 1997; 7: 120-4.
114. Guengerich FP, Shimada T. Oxidation of toxic and carcinogenic chemicals by human cytochrome P450 enzymes. Chem Res Toxicol 1991; 4: 391-407.
115. Testa B, Jenner P. Inhibitors of cytochrome P-450s and their mechanism of action. Drug Metab Rev 1981; 12: 1-117.
116. Chang TKH, Gonzalez FJ, Waxman DJ. Evaluation of triacetylole-andomycin, α-naftoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Arch Biochem Biophys 1994; 311: 437-42.
117. Newton DJ, Wang RW, Lu AYH. Cytochrome P450 inhibitors - evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 1995; 23: 154-8.
118. Ono S, Hatanaka T, Hotta H, Satoh T, Gonzalez FJ, Tsutsui M. Specificity of substrate and inhibitor probes for cytochrome P450s: Evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes. Xenobiotica 1996; 26: 681-93.
119. Ekins S, van den Branden M, Ring BJ, Wrighton SA. Examination of purported probes of human CYP2B6. Pharmacogenetics 1997; 7: 165-79.
120. Kharasch ED, Hankins DC, Baxter PJ, Thummel KE. Single-dose disulfiram does not inhibit CYP2A6 activity. Clin Pharmacol Ther 1998; 64: 39-45
121. Orrenius S, Nobel CSI, van den Dobbelsteen DJ, Burkitt MJ, Slater AFG. Dithiocarbamates and the redox regulation of cell death. Biochem Soc Trans 1996; 24: 1032-8.
122. Wolfe JT, Ross D, Cohen GM. A role for metals and free radicals in the induction of apoptosis in thymocytes. FEBS Lett 1994; 352: 58-62.
123. Verhaegen S, McGowan AJ, Brophy AR, Fernandes RS, Cotter TG. Inhibition of apoptosis by antioxidants in the human HL-60 leukemia cell line. Biochem Pharmacol 1995; 50: 1021-9.
124. Nobel CSI, Burgess DH, Zhivotovsky B, Burkitt MJ, Orenius S, Slater AFG. Mechanism of dithiocarbamate inhibition of apoptosis: Thiol oxidation by dithiocarbamate disulfides directly inhibits processing of the caspase-3 proenzyme. Chem Res Toxicol 1997; 10: 636-43.
125. Nobel CSI, Kimland M, Nicholson DW, Orrenius S, Slater AFG. Disulfiram is a potent inhibitor of proteases of the caspase family. Chem Res Toxicol 1997; 10: 1319-1324.
126. Nobel CSI, Kimland M, Lind B, Orrenius S, Slater AFG. Dithiocarbamates induce apoptosis in thymocytes by raising the intracellular level of redox-active copper. J Biol Chem 1995; 270: 26202-8.
127. Burkitt MJ, Bishop HS, Milne L, Tsang SY, Provan GJ, Nobel CSI, et al. Dithiocarbamate toxicity toward thymocytes involves their copper-catalyzed conversion to thiuram disulfides, which oxidize glutathione in a redox cycle without the release of reactive oxygen species. Arch Biochem Biophys 1998; 353: 73-84.
128. Aaseth J, Soli NE, Forre O. Increased brain uptake of copper and zinc in mice caused by diethyldithiocarbamate. Acta Pharmacol Toxicol 1979; 45: 41-4.
129. Trombetta LD, Toulon M, Jamall IS. Protective effects of glutathione on diethyldithiocarbamate (DDC) cyto-toxicity: A possible mechanism. Toxicol Appl Pharmacol 1988; 93: 154-64.
130. Iseki A, Kambe F, Okumura K, Hayakawa T, Seo H. Regulation of thyroid follicular cell function by intracellular redox-active copper. Endocrinology 2000; 141: 4373-82.
131. Allain P, Krari N. Diethyldithiocarbamate, copper and neurological disorders. Life Sci 1991; 48: 291-9.
132. Allain P, Krari N. Diethyldithiocarbamate and brain copper. Res Commun Chem Pathol Pharmacol 1993; 80: 105-112.
133. Tonkin EG, Erve JCL, Valentine WM. Disulfirain produces a non-carbon-disulfide-dependent Schwannopathy in the rat. J Neuropathol Exp Neurol 2000; 59: 786-97.
134. Tonkin EG, Valentine HL, Milatovic DM, Valentine WM. N,N-diethyldithiocarbamate produces copper accumulation, lipid peroxidation, and myelin injury in rat peripheral nerve. Toxicol Sci 2004; 81: 160-71.
135. Calviello G, Filippi GM, Toesca A, Palozza P, Maggiano N, Di Nicuolo F, et al. Repeated exposure to pyrrolidine-dithiocarbamate induces peripheral nerve alterations in rats. Toxicol Lett 2005; 158: 61-71
136. Valentine HL, Amarnath K, Amarnath V, Valentine WM. Dietary copper enhances the peripheral myelinopathy produced by oral pyrrolidine dithiocarbamate. Toxicol Sci 2006; 89: 485-94.
137. 2+ complex in the cultured rat cortical astrocytes. Glia 2000; 31: 249-61.
138. Kim CH, Kim JH, Xu J, Hsu CY, Ahn YS. Pyrrolidine dithiocarbamate induces bovine cerebral endothelial cell death by increasing the intracellular zinc level. J Neurochem 1999; 72: 1586-92.
139. Min YK, Park JH, Chang SA, Kim YS, Alm -YS, Seo JT, et al. Pyrrolidine dithiocarbamate-induced neuronal cell death is mediated by Akt, casein kinase 2, c-Jun N-terminal kinase, and I kappa B kinase in embryonic hippocampal progenitor cells. J Neurosci Res 2003; 71: 689-700.
140. 2+. Am J Physiol Cell Physiol 2000; 278: C1116-25.
141. Kimoto-Kinoshita S, Nishida S, Tomura TT. Diethyldithiocarbamate can induce two different type of death: Apoptosis and necrosis mediating the differential MAP kinase activation and redox regulation in HL60 cells. Mol Cell Biochem 2004; 265: 123 -32.
142. Chung KC, Park JH, Kim CH, Lee HW, Sato N, Uchiyama Y, et al. Novel biphasic effect of pyrrolidine dithiocarbamate on neuronal cell viability is mediated by the differential regulation of intracellular zinc and copper ion levels, NF-κB, and MAP kinases. J Neurosci Res 2000; 59: 117-25.
143. Della Ragione F, Cucciolla V, Borriello A, Della Pietra V, Manna C, Galletti P, et al. Pyrrolidine dithiocarbamate induces apoptosis by a cytochrome c-dependent mechanism. Biochem Biophys Res Common 2000; 268: 942-6.
144. Dumay A, Rincheval V, Trotot P, Mignotte B, Vayssiere JL. The superoxide dismutase inhibitor diethyldithiocarbamate has antagonistic effects on apoptosis by triggering both cytochrome c release and caspase inhibition. Free Radic Biol Mod 2006; 40: 1377-90.
145. Fuller RK, Gordis E. Does disulfiram have a role in alcoholism treatment today? Addiction 2004; 99: 21-4
146. Chick J. Safety issues concerning the use of disuffiram in treating alcohol dependence. Drug Saf 1999; 20: 427-35.
147. Friis H, Andreasen PB. Drug-induced hepatic injury - an analysis of 1100 cases reported to the Danish Committee on Adverse Drug -Reactions between 1978 and 1987. J Intern Med 1992; 232: 133-8.
148. Wright C, Vafier JA, Lake CR. Disulfiram-induced fulminating hepatitis - guidelines for liver panel monitoring. J Clin Psychiatry 1988; 49: 430-4.
149. Ellenhorn MJ. In: Schonwald S, Ordogand D, Wasserberger J Ed, Ellenhorn's medical toxicology. Diagnosis and treatment of human poisoning. Baltimore, Lippincott; Williams and Wilkins. 1997; 2: 340-9.
150. Loo TW, Clarke DM. Blockage of drug resistance in vitro by disulfiram, a drug used to treat alcoholism. J Natl Cancer Inst 2000; 92: 898-902
151. Sauna ZE, Peng XCH, Nandigarna K, Tekle S, Ambudkar SV. The molecular basis of the action of disuffiram as a modulator of the multidrug resistance-linked ATP binding cassette transporters MDR1 (ABCB1) and MRP1 (ABCCI). Mol Pharmacol 2004; 65: 675-84.
152. Shukla S, Sauna ZE, Prasad R, Ambudkar SV. Disuffiram is a potent modulator of multidrug transporter Cdr1p of Candida albicans. Biochem Biophys Commun 2004; 322: 520-5.
153. Sauna ZE, Shukla S, Ambudkar SV. Disulfiram, an old drug with new potential therapeutic uses for human cancers, and fungal infections. Mol Biosyst 2005; 1: 127-34.
154. Baldwin AS. The NF-κB and IκB proteins: New discoveries and insights. Annu Rev Immunol 1996; 14: 649-83.
155. Giardina C, Hubbard AK. Growing old with nuclear factor-βB. Cell Stress Chaperones 2002; 1: 207-12.
156. Bell S, Degitz K, Qurling M, Jilg N, Page S, Brand, K. Involvement of NF-κB signalling in skin physiology and disease. Cell Signal 2003; 15: 1-7.
157. Ruland J, Mak TW. Transducing signals from antigen receptors to nuclear factor κB. Immunol Rev 2003; 193: 93-100.
158. Santoro MG, Rossi A, Amici C. New EMBO member's review - NF-κB and virus infection: Who controls whom. EMBO J 2003; 22: 2552-60.
159. Kucharczak J, Simmons MJ, Fan YJ, Gelinas C. To be, or not to be: NF-κB is the answer: Role of Rel/NF-κB in the regulation of apoptosis. Oncogene 2003; 22: 8961-92.
160. Burstein E, Ducrett CS. Dying for NF-κB? Control of cell death by transcriptional regulation of the apoptotic machinery. Curr Open Cell Biol 2003; 15: 732-1.
161. Puel A, Picard C, Ku CL, Smahi A, Casanova JL. Inherited disorders of NF-κB-mediated immunity in man. Curr Opin Immunol 2004; 16: 34-41.
162. Bonizzi G, Karin M. The two NF-κB activation pathways and their role in innate and adaptive immunity. Trends Immunol 2004; 25: 280-8
163. Kumar A, Takada Y, Boriek AM, Aggarwal BB. Nuclear factor-κB: Its role in health and disease. J Mol Mod 2004; 82: 43448.
164. Meffert MK, Baltimore D. Physiological functions for brain NF-κB. Trends Neurosci 2005; 28: 37-43.
165. Natoli G, Saccani S, Bosisio D, Marazzi I. Interactions of NF-κB with chromatin: The art of being at the right place at the right time. Nat Immunol 2005; 6: 439-45.
166. Siebenlist U, Brown K, Claudio E. Control of lymphocyte development by NF-κB. Nat Rev Immunol 2005; 5: 435-45.
167. Courtois G. The NF-κB signaling pathway in human genetic diseases. Cell Mol Life Sci 2005; 62: 1682-91.
168. Jimi E, Ghoso S. Role of NF-κB in the immune system and bone. Immumol Rev 2005; 208: 80-7.
169. Xiao GT, Rabson AB, Young W, Qing GL, Qu ZX. Alternative pathways of NF-κB activation: A double-edged sword in health and disease. Cytokine Growth Factor Rev 2006; 17: 281-93.
170. Memet S. NF-κB functions in the nervous system: From development to disease. Biochem Pharmacol 2006; 72: 1180-95.
171. Dejardin E. The alternative NF-κB pathway from biochemistry to biology: Pitfalls and promises for future drug development. Biochem Pharmacol 2006; 72: 1161-79.
172. Gilmore TD. Introduction to NF-βB: Players, pathways, perspectives. Oncogene 2006; 25: 6680-4.
173. Hoffmann A, Natoli G, Ghosh G. Transcriptional regulation via the, NF-κB signaling module. Oncogene 2006; 6706-16.
174. Hayden MS, West AP, Ghosh S. NF-βB and the immune response. Oncogene 2006; 25: 6758-80.
175. Dutta J, Fan X, Gupta N, Fan G, Gelinas C. Current insights into the regulation of programmed cell death by NF-κB. Oncogene 2006; 25: 6800-16.
176. De Basscher K, Vanden Berghe W, Haegeman G. Cross-talk between nuclear receptors and NF-κB. Oncogene 2006; 25: 6868-86.
177. Barnes PJ, Larin M. Mechanisms of disease. Nuclear factor-κB - a pívótal transcription factor in chronic inflammatory disease. N Engl J Med 1997; 336: 1066-71.
178. Jobin C, Sartor RB. The IκB/NF-κB system: A key determinant of mucosal inflammation and protection. Am J Physiol Cell Physiol 2000; 278: C451-62.
179. Makarov SS. NF-κB as a therapeutic target in chronic inflammation: recent advances. Mol Med Today 2000; 6: 441-8.
180. Makarov SS. NF-κB in rheumatoid arthritis: A pivotal regulator of inflammation, hyperplasia, and tissue destruction. Arthritis Res 2001; 3: 200-6.
181. Kutuk O, Basaga H. Inflammation meets oxidation: NF-κB as a mediator of initial lesion development in atherosclerosis. Trends Mol Med 2003; 9: 549-57.
182. Monaco C, Paleolog E. Nuclear factor κB: A potential therapeutic target in atherosclerosis and thrombosis. Cardiovasc Res 2004; 61: 671-82.
183. Bacher S, Schmitz ML. The NF-κB pathway as a potential target for autoimmune disease therapy. Curr Pharm Des 2004; 10: 2827-37.
184. de Winther MPJ, Kanters E, Kraal G, Hofker MH. Nuclear factor κB signaling in atherogenesis. Arterioscler Thromb Vasc Biol 2005; 25: 904-14.
185. Xanthoulea S, Curfs DM, Hofker HM, de Windier MPJ. Nuclear factor kappaB signaling in macrophage function and atherogenesis. Curr Opin Lipidol 2005; 16: 536-42.
186. Liu SF, Malik AB. NF-κB activation as a pathological mechanism of septic shock and inflammation. Am J Physiol Lung Cell Mol Physiol 2006; 290: L622-45.
187. Park GY, Christman JW. Nuclear factor kappa B is a promising therapeutic target in inflammatory lung disease. Curr Drug Targets 2006; 7: 661-8
188. Roman-Blas JA, Jimenez SA. NF-κB as a potential therapeutic target in osteoarthritis and rheumatoid arthritis. Osteoarthritis Cartilage 2006; 14: 839-48.
189. Natoli G. Tuning up inflammation: How DNA sequence and chromatin organization control the induction of inflammatory genes by NF-κB. FEBS Lett 2006; 580: 2843-9.
190. Vanden Berghe W, Ndlovu MN, Hoya-Arias R, Dijsselbloem N, Gerlo S, Haegeman G. Keeping up NF-κB appearances: Epigenetic control of immunity or inflammation-triggered epigenetics. Biochem Pharmacol 2006; 72:1114-31.
191. Pazin MJ, Sheridan PL, Cannon K, Cao ZD, Keck JG, Kadonaga JT, et al. NF-κB-mediated chromatin reconfiguration and transcriptional activation of the HIV-1 enhancer in vitro. Genes Dev 1996; 10: 37-49.
192. DeLuca C, Kwon H, Lin RT, Wainberg M, Hiscott J. NF-κB activation and HIV-1 induced apoptosis. Cytokine Growth Factor Rev 1999; 10: 235-53.
193. West MJ, Lowe AD, Kam J. Activation of human immunodeficiency virus transcription in T cells revisited: NF-κB p65 stimulates transcriptional elongation. J Virol 2001; 75: 8524-37.
194. Pande V, Ramos MJ. Nuclear factor κB: A potential target for anti-HIV chemotherapy. Curr Med Chem 2003; 10: 1603-15.
195. Williams SA, Chen LF, Kwon H, Ruiz-Jarabo CM, Verdin E, Greene WC. NF-κB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. EMIBO J 2006; 25: 139-49.
196. Karin K Cao YX, Greten FR, Li ZW. NF-κB in cancer: From innocent bystander to major culprit. Nat Rev Cancer 2002; 2: 301- 10.
197. Haefner B. NF-κB: Arresting a major culprit in cancer. Drug Discov Today 2002; 7: 653-63.
198. Garg A, Aggarwal BB. Nuclear transcription factor-κB as a target for cancer drug development. Leukemia 2002; 16: 1053-68.
199. Richmond A. NF-κB, chemokine gene transcription and tumour growth. Nat Rev Immunol 2002; 2: 664-74.
200. Amit S, Ben-Neriah Y. NF-κB activation in cancer: A challenge for ubiquitination- and proteasome-based therapeutic approach. Semin Cancer Biol 2003; 13: 15-28.
201. Sun SC, Xiao GT. Deregulation of NF-κB and its upstream kinases in cancer. Cancer Metastasis Rev 2003; 22: 405-22.
202. Aggarwal BB. Nuclear factor-κB: The enemy within. Cancer Cell 2004; 6: 203-8.
203. Chen F. Endogenous inhibitors of nuclear factor-κB, an opportunity for cancer control. Cancer Res 2004; 64: 8135-8.
204. Nakanishi C, Toi M. Nuclear factor-κB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 2005; 5: 297-309.
205. Karin M, Greten FR. NF-κB: Linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005; 5: 749-59
206. Luo JL, Kamata H, Karin M. IKK/NF-κB signaling: Balancing life and death - a new approach to cancer therapy. J Clip Invest 2005; 115: 2625-32.
207. Olivier S, Robe P, Bours V. Can NF-κB be a target for novel and efficient anti-cancer agents? Biochem Pharmacol 2006; 72: 1054- 69.
208. Karin M. Nuclear factor-κB in cancer development and progression. Nature 2006; 441: 431-6.
209. Basseres DS, Baldwin AS. Nuclear factor-κB and inhibitor of κB kinase pathways in oncogenic initiation and progression. Oncogene 2006; 25. 6817-30.
210. Mattson MP, Culmsee C, Yu ZF, Camandola S. Roles of nuclear factor κB in neuronal survival and plasticity. J Neurochem 2000; 74; 443-56.
211. Koulich E, Nguyen T, Johnson K, Giardina CA, D. Mello SR. NF-κB is involved in the survival of cerebellar granule neurons: Association of IκB phosphorylation with cell survival. J Neurochem 2001; 76: 1188-98.
212. Blondeau N, Widmann C, Lazdunski M, Heurteauk C. Activation of the nuclear factor-κB is a key event in brain tolerance. J Neurosci 2001; 21: 4668-77.
213. Piccioli P, Porcile C, Stanzione S, Bisaglia M, Bajetto A, Bonavia R, et al. Inhibition of nuclear factor-κB activation induces apoptosis in cerebellar granule cells. J Neurosci Res 2001; 66: 1064-73.
214. Yalcin A, Koulich E, Mohamed S, Liu L, D'Mello SR. Apoptosis in cerebellar granule neurons is associated with reduced interaction between CREB-binding protein and NF-κB. J Neurochem 2003; 84: 397-408.
215. Nickols JC, Valentine W, Kanwal S, Carter BD. Activation of the transcription factor NF-κB in Schwann cells is required for peripheral myelin formation. Nat Neurosci 2003; 6: 161-7.
216. Gutierrez H, Hale VA, Dolcet X, Davies A. NF-kappa B signalling regulates the growth of neural processes in the developing PNS and CNS. Development 2005; 132: 1713-26.
217. Chen YLL, Law PY, Loh HH. Action of NF-κB on the delta opioid receptor gene promoter. Biochem Biophys Res Commun 2007; 352: 818-22
218. Ben-Neriah Y, Schmitz ML. Of mice and men. Meeting on the biology and pathology of NF-κB. EMBO Rep 2004; 5: 668-73.
219. Beinke S, Ley SC. Functions of NF-κB1 and NF-κB2 in immune cell biology. Biochem J 2004; 382: 393-409.
220. Miyamoto S, Verma IM. Rel/NF-κB/IκB story. Ady Cancer Res 1995; 66: 255-92.
221. Verma IM, Stevenson JK, Schwarz EM, Vanantwerp D, Miyamoto S. Rel/ NF-κB/IκB: Intimate tales of association and dissociation. Genes Dev 1995; 9: 2723-35.
222. May MJ, Ghosh S. Rel/NF-κB and IκB proteins: An overview. Semin Cancer Biol 1997; 8: 63-73.
223. Baeuerle PA. IκB-NF-κB structures: At the interface of inflammation control. Cell 1998; 95: 729-31.
224. May MJ, Ghosh S. Signal transduction through NF-κB. Immunol Today 1998; 19: 80-8.
225. Li X, Massa PE, Hanidu A, Peet GW, Aro P, Savitt A, et al. IKKu, IKKβ, and NEMO/IKKγ are each required for the NF-κB-mediated inflammatory response program. J Biol Chem 2002; 277: 45129- 40.
226. Israel A. NF-κB activation: Nondegradative ubiquitination implicates NEMO, Trends Immunol 2006; 27: 395-7.
227. Sebban H, Yamaoka S, Courtois G. Posttranslational modifications of NEMO and its partners in NF-κB signaling. Trends Cell Biol 2006; 16: 569-77.
228. Scheidereit C. IκB kinase complexes: Gateways to NF-κB activation and transcription. Oncogene 2006; 25: 6685-705.
229. Perkins ND. Integrating cell-signalling pathways with NF-κB and IKK function. Nat Rev Mol Cell Biol 2007; 8: 49-62.
230. Maniatis T. A ubiquitin ligase complex essential for the NF-κB, Wnt/Wingless; and Hedgehog signaling pathways. Genes Dev 1999; 13: 505-10.
231. Ghosh S, Karin M. Missing pieces in NF-κB puzzle Cell 2002; 109: S81-96.
232. Hayden MS, Ghosh S. Signaling to NF-κB. Genes Dev 2004; 18: 2195-224.
233. Chen LF, Greene WC. Shaping the nuclear action of NF-κB. Nat Rev Mol Cell Biol 2004; 5: 392-401.
234. Schreck R, Meier B, Mannel DN, Droge W, Baeuerle PA. Dithiocarbamates as potent inhibitors of nuclear factor κB activation in intact cells. J Exp Med 1992; 175: 1181-94.
235. Henkel T, Machleidt T, Alkalay I, Kronke M, Ben-Neriah Y, Baeuerle PA. Rapid proteolysis of IκB-α is necessary for activation of transcription factor NF-κB. Nature 1993; 365: 182-5.
236. Liu SF, Ye XB, Malik AB. Pyrrolidine dithiocarbamate prevents I-κB degradation and reduces microvascular injury induced by lipopolysaccharide in multiple organs. Mol Pharmacol 1999; 55: 658-67
237. Liu SF, Ye XB, Malik AB. In vivo inhibition of nuclear factor-κB activation prevents inducible nitric oxide synthase expression and systemic hypotension in a rat model of septic shock. J Immunol 1997; 159:3976-83.
238. Liu SF, Ye XB, Malik AB. Inhibition of NF-κB activation by pyrrolidine dithiocarbamate prevents in vivo expression of proinflammatory genes. Circulation 1999; 100: 1330-7.
239. Ross SD, Kron IL, Gangemi JJ, Shockey KS, Stoler M, Kern JA, et al. Attenuation of lung reperfusion injury after transplantation using an inhibitor of nuclear factor-κB. Am J Physiol Lung Cell Mol Physiol 2000; 279: L528-36.
240. Cuzzocrea S, Chatterjee PK, Mazzon E, Dugo L, Serraino I, Britti D, et al. Pyrrolidine dithiocarbamate attenuates the development of acute and-chronic inflammation. Br J Pharmacol 2002; 135: 496-510.
241. Ohta K, Nakayama K, Kurokawa T, Kikuchi T, Yoshimura N. Inhibitory effects of pyrrolidine dithiocarbamate on endotoxin-induced uveitis in Lewis rats. Invest Ophthalmol Vis Sci 2002; 43: 744-50.
242. Bruck R, Aeed H, Schey R, Matas Z, Reifen R, Zaiger G, et al. Pyrrolidine dithiocarbamate protects against thioacetamide-induced failure in rats. J Hepatol 2002; 36: 370-7.
243. Tamada S, Nakatani T, Asai T, Tashiro K, Komiya T, Sumi T, et al. Inhibition of nuclear factor-κB activation by pyrrolidine dithio-carbamate prevents chronic FK506 nephropathy. Kidney Int 2003; 63: 306-14.
244. Chatterjee PK, Bianca RDD, Sivarajah A, McDonald MC, Cuzzocrea S, Thiemermann C. Pyrrolidine dithiocarbamate reduces renal dysfunction and injury caused by ischemia/reperfusion of the rat kidney. Eur J Pharmacol 2003; 482: 271-80.
245. Cuzzocrea S, Rossi A, Pisano B, Di Paola R, Genovese T, Patel NSA, et al. Pyrrolidine dithiocarbamate attenuates the development of organ failure induced by zymosan in mice. Intensive Care Med 2003; 29: 2016-25.
246. La Rosa G, Cardali S, Genovese T, Conti A, Di Paola R, Le Torre D, et al. Inhibition of the nuclear factor-κB activation with pyrrolidine dithiocarbamate attenuating inflammation and oxidative stress after experimental spinal cord trauma in rats. J Neurosurg Spine 2004; 1: 311-21.
247. Yang CH, Fang IM, Lin CP, Yang CM, Chen MS. Effects of the NF-κB inhibitor pyrrolidine dithiocarbamate on experimentally induced autoimmune anterior uveitis. Invest Ophthalmol Vis Sci 2005; 46: 1339-47.
248. Muia C, Mazzon E, Maiere D, Zito D, Di Paola R, Domenico S, et al. Pyrrolidine dithiocarbamate reduced experimental periodontitis, Eur J Pharmacol 2006; 539: 205-10.
249. Li HL, Gu HY, Sun BG. Protective effects of pyrrolidine dithiocarbamate on myocardium apoptosis induced by adriamycin in rats. Int J Cardiol 2007; 114: 159-65.
250. Nathens AB, Bitar R, Davreux C, Bujard N, Marshall JC, Dackiw APB, et al. Pyrrolidine dithiocarbamate attenuates endotoxin-induced acute lung injury. Am J Respir Cell Mol Biol 1997; 17: 608-16.
251. Long SM, Laubach VE, Tribble CG, Kaza AK, Fiser SM, Cassada DC, et al. Pyrrolidine dithiocarbamate reduces lung reperfusion injury. J Surg Res 2003; 112: 12-18.
252. Munoz C, Pascual-Salcedo D, Castellanos MD, Alfranca A, Aragones J, Vara A. et al. Pyrrolidine dithiocarbamate inhibits the production of interleukin-6, interleukin-8, and granulocyte-macrophage colony-stimulating factor by human endothelial cells in response to inflammatory mediators: Modulation of NF-κB and AP-1 transcription factors activity. Blood 1996; 88: 3482-90.
253. He HJ, Zhu TN, Xie Y, Fan JS, Kole S, Saxena S, et al. Pyrrolidine dithiocarbamate inhibits interleukin-6 signaling through impaired STAT3 activation and association with transcriptional coactivators in hepatocytes. J Biol Chem 2006; 281: 31369-79.
254. Kao JJ. The NF-κB inhibitor pyrrolidine dithiocarbarnate blocks IL-1β induced hyaluronan synthase 1 (HAS1) mRNA transcription, pointing at NF-κB dependence of the gene HASI. Exp Gerontol 2006; 41: 641-7.
255. Slater AFG, Kimland M, Jiang SA, Orrenius S. Constitutive nuclear NF-κB/rel DNA-binding activity of rat thymocytes is increased by stimuli that promote apoptosis, but not inhibited by pyrrolidine dithiocarbamate. Biochem J. 1995; 312: 833-8.
256. Kim CH, Kim JH, Moon SJ, Hsu CY, Seo JT, Ahn YS. Biphasic effects of dithiocarbamates on the activity of nuclear factor-κB. Eur J Pharmacol 2000; 392: 133-6.
257. Mihm S, Galter D, Droge W. Modulltion of transcription factor NF-κB activity by intracellular glutathione levels and by variations of the extracellular cysteine supply. FASEB J 1995; 9: 246-52.
258. Michiels C, Minet E, Mottet D, Raes M. Regulation of gene expression by oxygen: NF-κB and HIF-1, two extremes. Free Radic Biol Med 2002; 33:1231-42.
259. Haddad JJ. Science review: Redox and oxygen-sensitive transcription factors in the regulation of oxidant-mediated lung injury: Role for nuclear factor-κB. Crit Care 2002; 6: 481-90.
260. Schreck R, Albermann K, Baeuerle PA. Nuclear factor κB: An. oxidative stress responsive transcription factor of eukaryotic cells (a review). Free Radic Res Commun 1992; 17: 221-37.
261. Liu JK, Shigenaga MK, Yan LJ, Mori A, Ames BN. Antioxidant activity of diethyldithiocarbamate. Free Radic Res 1996; 24: 461-72.
262. Li NX, Karin M. Is NF-κB the sensor. of oxidative stress? FASEB J 1999; 13: 1137-43.
263. Bowie A. O'Neill LAJ. Oxidative stress and nuclear factor-κB activation. A reassessment of the evidence in the light of recent discoveries. Biochem, Pharmacol. 2000; 59: 13-23.
264. Gloire B, Legrand-Poels S, Piette J. NF-κB activation by reactive oxygen species: Fifteen years later. Biochem. Pharmacol 2006; 72: 1493-1505.
265. Bubici C, Papa S, Dean K, Franzoso G. Mutual cross-talk between reactive oxygen species and nuclear factor-κB: Molecular basis and biological significance. Oncogene 2006; 25: 6731-48.
266. Kudrin AV. Trace elements in regulation of NF-κB activity. J Trace Elem Med Biol 2000; 14: 129-42.
267. Jeon KI, Jeong JY, Jue DM. Thiol-reactive metal compounds inhibit NF-κB activation by blocking IκB kinase. J Immunol 2000; 164: 5981-9.
268. Satake H, Suzuki K, Aoki T, Otsuka M, Sugiura Y, Yamamoto T, et al. Cupric ion blocks NF-κB activation through inhibiting the signal-induced phosphorylation of IκBα. Biochem Biophys Res Commun 1995; 216: 568-73.
269. Iseki A, Kambe F, Okumura K, Niwata S, Yamamoto R, Hayakawa T, et al. Pyrrolidine dithiocarbamate inhibits TNF-α-dependent activation of NF-κB by increasing intracellular copper level in human aortic smooth muscle cells. Biochem Biophys Res Commun 2000; 276: 88-92.
270. Persichini T, Percario Z, Mazzon E, Colasanti M, Cuzzocrea S, Musci G. Copper activates the NF-κB pathway in vivo. Antioxid Redox Signal 2006; 8: 1897-1904.
271. 2+ dependence, and differential half-site recognition. J Biol Chem 1991; 266:252-60.
272. Shumilla JA, Wetterhahn KE, Barchowsky A. Inhibition of NF-κB binding to DNA by chromium, cadmium, mercury, zinc, and arsenite in vitro: Evidence of a thiol mechanism. Arch Biochem Biophys 1998; 349:356-62.
273. Kim CH, Kim JH, Hsu CY, Ahn YS Zinc is requined in pyrrolidine dithiocarbamate inhibition of NF-κB activation. FEBS Lett 1999; 449: 28-32.
274. Ballatori N. Glutathione mercaptides as transport forms of metals. Adv Pharmacol 1994; 27: 271-98.
275. Brennan P, ONeill LAJ. 2-mercaptoethanol restores the ability of nuclear factor kappa B (NF-κB) to bind DNA in. nuclear extracts from interleukin 1-treated cells incubated with pyrollidine dithiocarbamate (PDTC). Evidence for oxidation of glutathione in the mechanism of inhibition of NF-κB by PDTC. Biochem J 1996; 320: 975-81.
276. Fernandez PC, Machado J, Heussler VT, Botteron C, Palmer GH, Dobbelaere DAE. The inhibition of NF-κB activation pathways and the induction of apoptosis by dithiocarbamates in T cells are blocked by the glutathione precursor N-acetyl-L-cysteine. Biol Chem 1999; 380: 1383-94.
277. Kim CH, Kim JH, Lee J, Hsu CY, Ahn YS. Thiol antioxidant reversal of pyrrolidine dithiocarbamate-induced reciprocal regulation of AP-1 and NF-κB. Biol Chem 2003; 384: 143-50.
278. Kim CH, Kim JH, Lee J, Ahn YS. Zinc-induced NF-κB inhibition can be modulated by changes in the intracellular metallothionein level. Toxicol Appl Pharmacol 2003; 190: 189-96.
279. Maupin-Furlow JA, Humbard MA, Kirkland PA, Li W, Reuter CJ, Wright AJ, et al. Proteasomes from structure to function: Perspectives from archaea. Curr Top Dev Biol 2006; 75: 125-69.
280. Kostova Z, Wolf DH. For whom the bell tolls: Protein quality control of the endoplasmic reticulum and the ubiquitin-proteasome connection. EMBO J 2003; 22: 2309-17.
281. Hershko A. The ubiquitin system for protein degradation and some of its roles in the control of the cell division cycle. Cell Death Differ 2005; 12: 1191-7.
282. McBride WH, Iwamoto KS, Syljuasen R, Pervan M, Pajonk F. The role of the ubiquitin/proteasome system in cellular responses to radiation. Oncogene 2003; 22: 5755-73.
283. Sutovsky P, Van Leyen K, McCauley T, Day BN, Sutovsky M. Degradation of paternal mitochondria after fertilization: Implications for heteroplasmy, assisted reproductive technologies and mtDNA inheritance. Reprod Biomed Online 2004; 8: 24-33.
284. Lipford JR, Deshaies RJ. Diverse roles for ubiquitin-dependent proteolysis in transcriptional activation. Nat Cell Biol 2003; 5: 845-50.
285. Muratani M, Tansey WP. How the ubiquitin-proteasome system controls transcription. Nat Rev Mol Cell Biol 2003; 4: 192-201.
286. Lassot I, Latreille D, Rousset E, Sourisseau M, Linares LK, Chable-Bessia C, et al. The proteasome regulates HIV-1 transcription by both proteolytic and nonproteolytic mechanisms. Mol Cell 2007; 25: 369-83.
287. Dunand-Sauthier I, Walker C, Wilkinson C, Gordon C, Crane R, Norbury C, et al. Sum1, a component of the fission yeast eIF3 translation initiation complex, is rapidly relocalized during environmental stress and interacts with components of the 26S proteasome. Mol Biol Cell 2002; 13: 1626-40.
288. Gillette TG, Huang W, Russell SJ, Reed SH, Johnston SA, Friedberg EC. The 19S complex of the proteasome regulates nucleotide excision repair in yeast. Genes Dev 2001; 15: 1528-39.
289. Lee D, Ezhkova E, Li B, Pattenden SG, Tansey WP, Workman JL. The proteasome regulatory particle alters the SAGA coactivator to enhance its interactions with transcriptional activators. Cell 2005; 123: 423-36.
290. Ferdous A, Gonzalez F, Sun L, Kodadek T, Johnston SA. The 19S regulatory particle of the proteasome is required for efficient transcription elongation by RNA polymerase II. Mol Cell 2001; 7: 981-91.
291. Gonzalez F, Delahodde A, Kodadek T, Johnston SA. Recruitment of a 19S proteasome subcomplex to an activated promoter. Science 2002; 296: 548-50.
292. Nishiyama A, Tachibana K, Igarashi Y, Yasuda H, Tanahashi N, Tanaka K, et al. A nonproteolytic function of the proteasome is required for the dissociation of Cdc2 and cyclin B at the end of M phase. Genes Dev 2000; 14: 2344-57.
293. Dicato M, Boccadoro M, Cavenagh J, Harousseau JL, Ludwig H, San Miguel J, et al. Management of multiple myeloma with bortezomib: Experts review the data and debate the issues. Oncology 2006; 70: 474-82.
294. Kisselev AF, Goldberg AL. Proteasome inhibitors: From research tools to drug candidates. Chem Biol 2001; 8: 739-58.
295. Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 2004; 5: 417-21.
296. Adams J. The proteasome: A suitable antineoplastic target. Nat Rev Cancer 2004; 4: 349-60.
297. Nalepa G, Rolfe M, Harper JW. Drug discovery in the ubiquitin-proteasome system. Nat Rev Drug Discov 2006; 5: 596-613.
298. Nencioni A, Grunebach F, Patrone F, Ballestrero A, Brossart P. Proteasome inhibitors: Antitumor effects and beyond. Leukemia 2007; 21: 30-6.
299. Bonamico M, Mazzone G, Vaciago A, Zambonelli L. Structural studies of metal dithiocarbamates. III. The crystal and molecular structure of zinc diethyldithiocarbamate. Acta Crystallogr 1965; 19: 898-909.
300. Farmer PJ, Gidanian S, Shahandeh B, Di Bilio AJ, Tohidian N, Meyskens FL. Melanin as a target for melanoma chemotherapy: Pro-oxidant effect of oxygen and metals on melanoma viability. Pigment Cell Res 2003; 16: 273-9.
301. Cen D, Brayton D, Shahandeh B, Meyskens FL, Farmer PJ. Disulfiram facilitates intracellular Cu uptake and induces apoptosis in human melanoma cells. J Med Chem 2004; 47: 6914-20.
302. Viola-Rhenals M, Rieber MS, Rieber M. Suppression of survival in human SKBR3 breast carcinoma in response to metal-chelator complexes is preferential for copper-dithiocarbamate. Biochem Pharmacol 2006; 71: 722-34.
303. Morais C, Pat B, Gobe G, Johnson DW, Healy H. Pyrrolidine dithiocarbamate exerts anti-proliferative and pro-apoptotic effects in renal cell carcinoma cell lines. Nephrol Dial Transplant 2006; 21: 3377-88.
304. Wickstrom M, Danielsson K, Rickardson L, Gullbo J, Nygren P, Isaksson A, et al. Pharmacological profiling of disulfiram using human tumor cell lines and human tumor cells from patiens. Biochem Pharmacol 2007; 73: 25-33.
305. Brar SS, Grigg C, Wilson KS, Holder WD, Dreau D, Austin C, et al. Disulfiram inhibits activating transcription factor/cyclic AMP-responsive element binding protein and human melanoma growth in a metal-dependent manner in vitro, in mice and in a patient with metastatic disease. Mol Cancer Ther 2004; 3: 1049-60.
306. Si X, McManus BM, Zhang JC, Yuan J, Cheung C, Esfandiarei M, et al. Pyrrolidine dithiocarbamate reduces coxsackievirus B3 replication through inhibition of the ubiquitin-proteasome pathway. J Virol 2005; 79: 8014-23.
307. Krenn BM, Holzer B, Gaudemak E, Triendl A, van Kuppeveld FJ, Seipelt J. Inhibition of polyprotein processing and RNA replication of human rhinovirus by pyrrolidine dithiocarbamate involves metal ions. J Virol 2005; 79: 13892-9.
308. Amici M, Forti K, Nobili C, Lupidi G, Angeletti M, Fioretti E, et al. Effect of neurotoxic metal ions on the proteolytic activities of the 20S proteasome ftom bovine brain. J Biol Inorg Chem 2002; 7: 750-6.
309. 2+-induced reversible dissociation of subunit Rpn 10/p54 of the Drosophila 26 S proteasome. Biochem J 2005; 391: 301-10.
310. Kim I, Kim CH, Kim JH, Lee J, Choi JJ, Chen ZA, et al. Pyrrolidine dithiocarbamate and zinc inhibit proteasome-dependent proteolysis. Exp.Cell Res 2004; 298: 229-38.
311. Chen D, Peng FY, Cui QC, Daniel KG, Orlu S, Liu JG, et al. Inhibition of prostate cancer cellular proteasome activity by a pyrrolidine dithiocarbamate-copper complex is associated with suppression of proliferation and induction of apoptosis. Front Biosci 2005; 10: 2932-9.
312. Daniel KG, Chen D, Orlu S, Cui QC, Miller FR, Dou QP. Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells. Breast Cancer Res 2005; 7: R897-908.
313. Chen D, Cui QC, Yang H, Dou QP. Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. Cancer Res 2006; 66: 10425-33.
314. Marzano C, Bettio F, Baccichetti F, Trevisan A, Giovagnini L, Fregona D. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity. Chem Biol Interact 2004; 148: 37-48.
315. Giovagnini L, Ronconi L, Aldinucci D, Lorenzon D, Sitran S, Fregona D. Synthesis, characterization, and comparative in vitro cytotoxicity studies of platinum(II), palladium(II), and gold(III) methylsarcosinedithiocarbamate complexes. J Med Chem 2005; 48: 1589-95.
316. Ronconi L, Marzano C, Zanello P, Corsini M, Miolo G, Macca C, et al. Gold(III) dithiocarbamate derivatives for the treatment of cancer: Solution chemistry, DNA binding, and hemolytic properties. J Med Chem 2006; 49: 1648-57.
317. Daniel KG, Gupta P, Harbach RH, Guida WC, Dou QP. Organic copper complexes as a new class of proteasome inhibitors and apoptosis inducers in human cancer cells. Biochem Pharmacol 2004; 67: 1139-51.
318. Adsule S, Barve V, Chen D, Ahmed F, Dou QP, Padhye S, et al. Novel Schiff base copper complexes of quinoline-2 carboxaldehyde as proteasome inhibitors in human prostate cancer cells. J Med Chem 2006; 49: 7242-6.
319. Fang S, Lorick KL, Jensen JP, Weissman AM. RING finger ubiquitin protein ligases: Implications for tumorigenesis, metastasis and for molecular targets in cancer. Semin Cancer Biol 2003; 13: 5-14.
320. Hayakawa M, Miyashita H, Sakamoto I, Kitagawa M, Tanaka H, Yasuda H, et al. Evidence that reactive oxygen species do not mediate NF-κB activation. EMBO J 2003; 22: 3356-66.
321. Burger AM, Phatak P, Wilson M, Seth AK. Disulfiram inhibits the E3 ligase activity of breast cancer associated gene 2 (BCA2) and the growth of BCA2-expressing breast cancers in vitro and in vivo. Eur J Cancer Suppl. 2006; 4: 118.
322. Berndt C, Bech-Otschir D, Dubiel W, Seeger M. Ubiquitin system: JAMMing in the name of the lid. Curr Biol 2002; 12: R815-7.
323. Ambroggio XI, Rees DC, Deshaies RJ. JAMM: A metalloprotease-like zinc site in the proteasome and signalosome. PLoS Biol 2004; 2: 113-9.
324. Cope GA, Suh GSB, Aravind L, Schwarz SE, Zipursky SL, Koonin EV, et al. Role of predicted metalloprotease motif of Jab1/Csn5 in cleavage of Nedd8 from Cull. Science 2002; 298: 608-11.
325. Verma R, Aravind L, Oania R, McDonald WH, Yates JR, Koonin EV, et al. Role of Rpn11 metalloprotease in deubiquitination and degradation by the 26S proteasome. Science 2002; 298: 611-5.
326. Lipscomb WN, Strater N. Recent advances in zinc enzymology. Chem Rev 1996; 96: 2375-433.
327. Shiah SG, Kao YR, Wu FYH, Wu CW. Inhibition of invasion and angiogenesis by zinc-chelating agent disulfiram. Mol Pharmacol 2003; 64: 1076-84
328. 2 and antioxidants have opposite effects on activation of NF-κB and AP-1 in intact cells: AP-1 as secondary antioxidant-responsive factor. EMBO J 1993; 12: 2005-15.
329. Hartsfield CL, Alam J, Choi AMK. Transcriptional regulation of the heme oxygenase 1 gene by pyrrolidine dithiocarbamate. FASEB J 1998; 12: 1675-82.
330. Borrello S, Demple B. NF-κB-independent transcriptional induction of the human manganous superoxide dismutase gene. Arch Biochem Biophys 1997; 348: 289-94.
331. Wu WT, Chi KH, Ho FM, Tsao WC, Lin WW. Proteasome inhibitors up-regulate haem oxygenase-1 gene expression: Requirement of p38 MAPK (mitogen-activated protein kinase) activation but not of NF-κB (nuclear factor κB) inhibition. Biochem J 2004; 379: 587-93.
332. Nabhan JF, Ribeiro P. The 19 S proteasomal subunit POH1 contributes to the regulation of c-Jun ubiquitination, stability, and sub-cellular localization. J Biol Chem 2006; 281: 16099-107.
333. Concannon CG, Koehler BF, Reimertz C, Murphy BM, Bonner C, Thurow N, et al. Apoptosis induced by proteasome inhibition in cancer cells: predominant role of the p53/PUMA pathway. Oncogene 2007; 26: 1681-92.
334. Furuta S, Ortiz F, Sun XZ, Wu HH, Mason A, Momand J. Copper uptake is required for pyrrolidine dithiocarbamate-mediated oxidation and protein level increase of p53 in cells. Biochem J 2002; 365: 639-48.
335. Lee EW, Oh W, Song J. Jab1 as a mediator of nuclear export and cytoplasmic degradation of p53. Mol Cells 2006; 22: 133-40.
336. Pande V, Ramos MJ. NF-κB in human disease: Current inhibitors and prospects for de novo structure based design of inhibitors. Curr Med Chem 2005; 12: 357-74.
337. Coish PDG, Wickens PL, Lowinger TB. Small molecule inhibitors of IKK kinase activity. Expert Opin Ther Pat 2006; 16: 1-12.
338. Stevens M, Pannecouque C, De Clercq E, Balzarini J. Pyridine N-oxide derivatives inhibit viral transactivation by interfering with NF-κB binding. Biochem Pharmacol 2006; 71: 1122-35.
339. Gilmore TD, Herscovitch M. Inhibitors of NF-κB signaling: 785 and counting. Oncogene 2006; 25: 6887-99.
340. Nam NH. Naturally occurring NF-κB inhibitors. Mini Rev Med Chem 2006; 6: 945-51.
341. Calzado MA, Bacher S, Schmitz ML. NF-κB inhibitors for the treatment of inflammatory diseases and cancer. Curr Med Chem 2007; 14: 367-76.
342. Lombardi P, Fournier M, Bernier J, Mansour S, Neveu P, Krzystyniak K. Evaluation of the immunomodulatory potential of diethyl dithiocarbamate derivatives. Int J Immunopharmacol 1991; 13: 1073-84.
343. Segovia N, Crovetto G, Lardelli P, Espigares M. In vitro toxicity of several dithiocarbamates and structure-activity relationships. J Appl Toxicol 2002; 22: 353-7.
344. Milacic V, Chen D, Ronconi L, Landis-Piwowar KR, Fregona D, Dou QP. A novel anticancer gold(III) dithiocarbamate compound inhibits the activity of a purified 20S proteasome and 26S proteasome in human breast cancer cell cultures and xenografts. Cancer Res 2006; 66: 10478-86.